Stay updated on ARRY-382 Combo With Pembrolizumab in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the ARRY-382 Combo With Pembrolizumab in Solid Tumors Clinical Trial page.

Latest updates to the ARRY-382 Combo With Pembrolizumab in Solid Tumors Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.0%
- Check20 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference0.7%
- Check27 days agoNo Change Detected
- Check49 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check56 days agoChange DetectedThe webpage has added a section with helpful links provided by Pfizer, which includes information on how to obtain contact details for a study center nearby.SummaryDifference0.3%
- Check63 days agoChange DetectedThe webpage has undergone significant content changes, including the removal of detailed descriptions of a clinical study involving ARRY-382 and pembrolizumab, while retaining the study's identifier and revision number.SummaryDifference12%
- Check70 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
Stay in the know with updates to ARRY-382 Combo With Pembrolizumab in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ARRY-382 Combo With Pembrolizumab in Solid Tumors Clinical Trial page.